Boehringer Ingelheim recognized for its efforts to enhance access to medicine
Shares
Boehringer Ingelheim has been ranked among the top 20 largest pharmaceutical companies globally for the second time. The company ranked top for its ongoing effort to overcoming barriers to access to healthcare, especially for vulnerable groups and communities in developing countries.
The biopharmaceutical company was ranked at number 12 amongst 20 of the largest pharmaceutical companies. This is two positions higher from last year in the bi-annual global Access-to-Medicine Index.
The Access-To-Medicine ranking report acknowledges Boehringer Ingelheim’s solid foundation in Research and Development (R&D). For several years, Boehringer Ingelheim has made dedicated investments in R&D areas that are aligned with the focus of the index. This includes the Research Beyond Borders program. With the program, the company continues its search for new therapies for diseases such as TB, HBV and Dengue fever